Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01647308 · ClinicalTrials.gov registry record · Phase 2
Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes
A Phase 2 study, sponsored by Ionis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT01647308 is a Phase 2 study that was terminated before completion, run by Ionis Pharmaceuticals. The registered enrollment target is 15 participants.
The verdict
NCT01647308, a Phase 2 study, was terminated before completion, sponsored by Ionis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects of ISIS ISIS-APOCIIIRX on Triglyceride Levels and Insulin Sensitivity in Subjects with Type 2 Diabetes on stable treatment with metformin.
Interventions
- DRUG Placebo
- DRUG ISIS-APOCIIIRX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2012-07 |
| Est. Completion | 2014-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01647308
The ClinicalTrials.gov registry entry for NCT01647308 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01647308 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01647308 about?
NCT01647308 is a clinical study titled "Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes". The purpose of this study is to evaluate the effects of ISIS ISIS-APOCIIIRX on Triglyceride Levels and Insulin Sensitivity in Subjects with Type 2 Diabetes on stable treatment with metformin.
What is the current status of trial NCT01647308?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2012-07. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01647308?
The interventions under investigation include: Placebo (DRUG), ISIS-APOCIIIRX (DRUG).
Who is sponsoring clinical trial NCT01647308?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.